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ABSTRACT
 
Objective:
 
To estimate the cost–utility of adjuvant high-
dose interferon in high-risk melanoma patients in Quebec
compared to a watchful waiting strategy.
Method: A Markov model was developed that replicates
the ﬁndings of the pivotal E1684 trial. It was then used to
extrapolate survival over a period of 35 years. Costs of
medical resources used during the ﬁrst year were derived
through a detailed analysis of a sample (n = 13) of
patients treated in a leading academic hospital. Follow-up
costs were assessed through a medical decision algorithm.
Utilities were derived from a population-based survey
(n = 104) in different locations in Quebec using the time
trade-off method.
Results: The mean incremental cost per quality-adjusted
life-year of adjuvant Interferon therapy is equal to
CAN$55,090 over a follow-up of 7 years but drops
down to CAN$14,003 when extrapolated over 35
years.
Conclusions: Estimates of the cost-effectiveness of
high-dose interferon in melanoma patients show an
acceptable cost-effectiveness ratio if long-term survival
is taken into account. Estimates are, however, strongly
inﬂuenced by the observed trial differences in survival,
the utility associated to health states, and the discount
rate.
Keywords: cost–utility, economics, interferon, melanoma.
 
Introduction
 
In Canada, as in other countries, the incidence of
melanoma in the adult population has been increas-
ing. In 2001, the incidence in Canada was estimated
at 11 of 100,000 people and at 7 of 100,000 people
in Quebec or about 280 expected new cases per year
in that province [1]. Mortality due to melanoma is
lower and estimated at 2.9 of 100,000 people as a
number of melanomas are detected at an early stage
(stage I) with good prognosis. Major factors for
prognosis are the depth of vertical invasion of the
derma, the invasion of lymphatic nodes and metas-
tasis. These deﬁne four stages as described by the
American Joint Committee on Cancer (AJCC) [2]
and have recently been updated [3].
Usual therapy consists of surgical resection of the
tumor, including sometimes lymphatic vessels resec-
tion and various adjuvant treatments including
radiotherapy, chemotherapy, and immunotherapy.
But the overall results of these various adjuvant
treatments have been generally poor [4].
More recently the use of high-dose interferon-
alpha-2b has been showed to increase overall sur-
vival (OS)and/or disease-free survival in two bench-
mark trials [5–8].
In the Eastern Cooperative Oncology Group
(ECOG) trial E1684, 287 patients with stage IIB
and IIIA, B were given high-dose interferon (HDI)
over 1 year and followed up over a period of
7 years. This pivotal trial proved fundamental in
establishing the acceptance of interferon as adju-
vant therapy by the Federal Drug Administration
(FDA) and the Committee for Medicinal Products
for Human Use (CHMP) of the European Medi-
cines Agenct (EMEA). A second trial, ECOG trial
E1690, combined a low-dose interferon (LDI) and
an HDI group in similar stages II and III.
In the ECOG E1684 trial a clear beneﬁt at 7 years
was observed with a median survival of 2.78 years
versus 3.82 years and an estimated 5-year survival
of 37% versus 26%. The E1690 trial, however,
showed no signiﬁcant difference in survival at
4.7 years of follow-up but did show a difference in
relapse-free survival (RFS) with a hazard ratio of
1.28 for the HDI arm compared to observation.
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The HDI arm was similar to that of the E1684
trial, whereas the LDI arm used a more reduced reg-
imen of 3 MU/m
 
2
 
/d three times per week (TIW)
with a median follow-up of 52 months (4.3 years).
Comparison with the E1684 trial of the HDI arm
showed better results on OS and RFS in the E1690
trial with, respectively, a 5-year RFS of 37% and
44% and a 5-year OS of 46% and 53%.
Thus, an absolute difference of 7% at 5 years is
observed both on RFS and OS between the two
trials.
On the other hand the OS rate in the observation
arm of the E1690 trial was much improved also
compared to the survival of similar patients of the
E1684  trial.  This  discrepancy  was  explained  by
the investigators by the use of HDI salvage therapy
in recurred patients of the observation arm, thereby
boosting their survival time after recurrence [8].
The overall cost-of-illness on health-care systems
of melanoma has been estimated for the United
States at 563 million USD [9]. Comparable ﬁgures
for Europe are not available but are expected to
increase over time in parallel with increasing inci-
dence of melanoma and the use of more expensive
therapy. As health-care systems are, however, limited
in their ﬁnancial resources, any new medical therapy
that drains additional ﬁnancial resources should be
subjected to a scrutiny of its cost–effectiveness.
The present study intends to determine the com-
parative health gains and costs from the perspective
of the health-care system in the province of Quebec,
Canada, of an HDI adjuvant therapy compared to
observation alone, using a simulation model to
extrapolate the results of the E1684 trial over the
long term, and to compare these results with previ-
ous published economic evaluations of high-dose
adjuvant interferon therapy.
 
Patients and Methods
 
A hypothetical cohort of 1000 patients with stage
II–III and demographic characteristics similar to the
E1684 trial was considered as a starting point. A
Markov model was constructed in order to replicate
the trial ﬁndings over the ﬁrst 7 years on survival
and recurrence of the ECOG E1684 trial and then
used to extrapolate the results over a 35-year period
of the disease-speciﬁc survival of these patients.
Life-years gained were also adjusted for quality-of-
life to take into account toxicities and metastatic
recurrence of melanoma through a utility measure.
 
Structure of the model.
 
The Markov model con-
sists of four separate health states similar to those
used in the model developed by Hillner (Fig. 1)
[10,11]:
1. HDI treatment including possible toxicities
(ﬁrst year only);
2. alive with no symptoms, i.e., disease-free off-
treatment;
3. alive with recurrence, and;
4. death.
The patients enter the model after surgery, when
interferon treatment is initiated.
The model uses an annual cycle length, during
which patients can stay symptom-free, recur, or
die. No difference was made between local and
systemic recurrence, as no separate data were
available from the E1684 trial so that the recur-
rence state is a mixture of both with a majority of
distant metastasis.
All patients treated with interferon ﬁrst pass
through the initial therapy state. Patients in the
observation arm skip the interferon treatment dur-
ing the ﬁrst year and are directly allocated through
one of the other health states.
At the end of each yearly cycle, patients transit to
the next health state.
Transition probabilities for recurrence and death
were extracted from the published E1684 data
[5,6,8] and adjusted until a close ﬁt between the
model events and the trial events was achieved over
the duration of the trial up to 7 years.
Yearly recurrence probabilities and death proba-
bilities vary yearly during the ﬁrst 7 years in a
grossly declining fashion from a high of 0.28 to
0.11 for recurrence and 0.24 to 0.06 for death for
the Interferon arm with the years 2 to 4 presenting
the highest risk. After year 7, a recurrence proba-
bility of 0.054 was assumed until year 10, followed
by an annual constant probability of 0.025 of death
over the rest of the lifetime based on the 1-year risk
rates at 12 and 13 years by Slingluff et al.[12].
Long-term (after year 7) recurrence rates were
assumed to lead to death within 12 months on aver-
age so that no separate probability for recurrence
distinct from death was introduced after year 7.
 
Figure 1
 
State transition Markov model structure. IFN, interferon;
HD, high dose.
Surgery
IFM + HD(tox)
Relapse Disease-freewithout
symptoms
Death
0.24
0.370.39
T = 0
ﬁrst year
Start of
year 2
P =
 1
Start of
year 1
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Model assumptions.
 
Any model requires assump-
tions. This model assumed the following:
1. Most patients with long-term recurrence do not
survive beyond 12 months in practice [13] as
most long-term recurrences are metastatic dis-
tant recurrences and the duration between
recurrence and death is independent from time
since initial therapy.
2. There are no differences in the cost or medical
treatment for recurrence or terminal care of
patients with or without adjuvant HDI. This is
especially important regarding the use of inter-
feron salvage therapy in case of systemic recur-
rence in the control arm.
3. Beyond the ﬁrst year there are no differences in
intensity of follow-up or surveillance between
the patients treated with interferon and those in
the control arm.
4. Only disease-related death rates were incor-
porated over the long term as presumably
reported by Slingluff et al. [12]; no explicit
adjustment for an additional overall popula-
tionwide nonmelanoma death rate was made.
As a matter of fact published survival esti-
mates for melanoma patients do not make
the distinction between melanoma-related
deaths and deaths of other causes. Given that
the majority of patients are between 20 and
60 years old at the time of diagnosis the
reported death rates at 10 or even 15 years
of follow-up would mainly be melanoma-
related.
 
Analyses
 
Baseline model choices.
 
The baseline event param-
eters were chosen to most closely reﬂect the model
developed by Hillner for the United States in order
to facilitate comparisons with Quebec. This led us
to use the same post-trial recurrence probabilities
and the same model structure while reﬂecting local
practice and local unit prices in our cost estimates
(see Table 1 for baseline values).
 
Sensitivity analysis.
 
Several parameters were uncer-
tain in our analysis, they were therefore investigated
using univariate and probabilistic sensitivity analy-
sis and also introduced with the speciﬁc aim to
make comparisons with other published estimates
more easily.
 
Interferon Dose
 
We assumed a dose compliance of 60%, 80%, and
100% based on the original Kirkwood regimen and
a body surface area of 1.7 m
 
2
 
, once for a unit price
of interferon per MU of CAN$8 and once for a unit
price of CAN$16.
 
Disease-Free Follow-up Costs
 
To be made comparable to those used by González-
Larriba et al. [14] and also put equal to zero as in
the analysis by Hillner et al. [11], the annual follow-
up costs were tripled.
 
Cost of  Recurrence
 
Although our cost estimates are very close to those
of González-Larriba et al. [14], they might be
underestimated as they were based on hypothetical
standard care patterns. We therefore increased our
cost of recurrence by 50% to be closer to the Hillner
et al. [11] estimates. We also set the cost of RFS,
recurrence and terminal care to zero as in the anal-
ysis by Messori et al. [15].
 
Utility Estimates
 
As the standard gamble estimates by Kilbridge et al.
[16] proved to be very different from our time
trade-off (TTO) estimates we also ran a simulation
using an average utility of 0.83 for interferon cor-
responding to severe toxicity, which was a conserv-
ative estimate, and a utility of 0.60 for recurrence
and of 0.96 for recurrence-free survival without
symptoms. We also used the median interferon
treatment utility equal to 0.58 and metastatic recur-
rence preference at 0.08 from our TTO valuation
exercise.
 
Discount Rates
 
The discount rate for costs and effects was set to
6% as used by González-Larriba et al. [14], and
also set to zero to provide a plausible range of rec-
ommended and observed discount rates, with the
same discount rate applied to both costs and effects.
 
Post-Trial Survival Rates
 
Interferon  patients  only.
 
In our model, post-trial
long-term (systemic) recurrence rates were set at
 
Table 1
 
Baseline parameters
 
Interferon treatment cost (ﬁrst year) CAN$36,125
Yearly follow-up routine cost CAN$277–133–90
Cost of  recurrence and terminal care CAN$12,340
Annual post-trial death rate year 8 to 9 0.054
Annual post-trial death rate year 10 to 35 0.025
Utility interferon treatment 0.52
Utility metastatic recurrence 0.23
Utility disease-free 1
Discount rate 3%
 Crott et al.
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2.5% per year in accordance with the estimates used
by Hillner et al. [11] and as reported by Slingluff
et al. [12]. The interferon arm in the E1684 trial,
however, shows a ﬂattening of the survival curve
toward the end of the trial in the last 2 years, and
therefore a low hazard rate for death, although this
is most probably because of the small number of
patients remaining at risk at the end of the trial.
Messori et al. [15] used a ﬁtted parametric Gom-
pertz curve to extrapolate survival beyond the trial
data and estimated the relative death risk of patients
treated with interferon compared to patients
received no interferon treatment at 0.67 [95% con-
ﬁdence interval (CI) 0.49–0.91]. We therefore reran
the model using a post-trial annual death risk of
patients treated with interferon of 1.825% for the
interferon arm, while keeping the death risk for the
observational arm at 2.5% (carry-over model).
Alternatively we also allowed for a higher post-trial
recurrence rate of 5% in the interferon arm while
setting the recurrence rate in the control arm once at
1.825% and once at 0%. This forces the interferon
survival curve to cross the control survival curve
around 12 or 25 years (late and early crossover
model). The early crossover model can be consid-
ered as a worse case scenario where the early gain of
interferon in the trial period is lost after the trial,
because patients treated with interferon have a
higher post-trial death rate.
 
Interferon and observational arm.
 
The recent pub-
lication of ECOG trial E1690 preliminary results
showed an increased absolute survival rate in both
the HDI arm and the observational arm compared
to the E1684 trial, which is not completely
explained at the time of writing. As a ﬁrst step
toward an analysis of these data we ran a simula-
tion where we decreased both the interferon and
control post-trial annual death rates ﬁrst to 1.825%
per year (optimistic model) and then to 0% assum-
ing a post-trial “cure” model. Finally, we also
simulated a “drop-dead” model with the annual
post-trial death rates equal to 25% in both arms.
 
Stochastic Sensitivity Analysis
 
From the above univariate sensitivity analysis
results the most inﬂuencing parameters were used to
run a multivariate Monte-Carlo simulation using a
mix of distributions in a simultaneous way more
than 1500 samples. All stochastic variables were
uncorrelated with each other.
The following distributions were used:
1. The annual cost of Interferon reﬂecting a com-
bination of unit cost and dosage (truncated
normal, mean: CAN$36,000, range:
CAN$22,000–50,000). We used a truncated
normal distribution to cover the published cost
estimates of interferon therapy in different
countries and multiple combinations of unit
prices and dosages, centered on the observed
mean cost in our Quebec patient sample, and
truncated at plausible minimum and maximum
1-year costs as observed both in Europe and the
United States.
2. The annual post-trial death rate in both arms:
(triangular, mean: 2.5%, range: 1.8%
 
-
 
5%).
3. The average estimated utility of interferon
treatment (uniform, range: 0.62–0.86) and
recurrence of melanoma (uniform, range: 0.23–
0.52). A uniform distribution was chosen in
order to represent the large uncertainty cur-
rently surrounding the best choice of preference
measurement both with regard to the elicitation
method and the population of reference. The
boundaries of the distribution were chosen to
encompass published estimates as well as our
own elicitation results but without privileging
one of these as a more centered distribution
would do.
This allows us to obtain a distribution and a
standard deviation for the incremental cost–effec-
tiveness ratio (ICER) by a so-called second order
Monte-Carlo simulation. All simulations were car-
ried out with @Risk Software (Version 3.5.2, Pali-
sade Corp., Williamstown, MA, USA, 1997).
 
Costs
 
Interferon  treatment  costs.
 
The perspective taken
for assessing costs is that of the Ministry of Health
and Public Provincial Payers (Regie de l’Assurance-
Maladie du Quebec). Interferon dosage was based
on a retrospective chart analysis of a sample
(n 
 
=
 
 18) of patients in stage III treated at the Royal
Victoria Hospital in Montreal between August
1998 and September 1999. These patients repre-
sented half of patients with phase III disease treated
in Quebec so that they were considered as fairly rep-
resentative for the whole of the province.
Four of these patients stopped interferon treat-
ment during the ﬁrst year either because of distal
metastasis or because of enzymatic liver toxicity. In
11 of the patients (i.e., 61%) a dose reduction or
dose delay was observed. Overall administrated
dose was equal to 78% of the theoretical dose as
deﬁned in the Kirkwood protocol (i.e., 20 MU/m
 
2
 
/d
intravenous 5 times weekly for 4 weeks 
 
+
 
 10 MU/
m
 
2
 
/d subcutaneous 3 times weekly for 48 weeks).
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This level of side effects is comparable with that
observed in the E1684 trial where 66% of the
patients had at least a grade 3 adverse event and
14% had a grade 4 event with myelosuppression
occurring in almost all patients. Most of the side
effects were, however, reversible by interruption of
therapy or dose reductions. In the E1684 trial 50%
of the patients had a dose reduction or dose delay,
with however, 74% of the patients able to continue
their treatment for 1 year or until relapse. So our
sample of patients seems to be fairly typical of
patients treated with HDI [17].
Intravenous interferon costs were based on the
acquisition cost of the Hospital Pharmacy at
CAN$8.16 per MU and at CAN$14.17 per MU on
average for the subcutaneous maintenance inter-
feron at retail pharmacy prices (1999 prices).
The average cost for the interferon adjuvant treat-
ment over 1 year was equal to CAN$34,979. This
accounted for more than 96% of the total cost of the
interferon therapy. Incorporating the costs of spe-
cialist visits, laboratory tests, concomitant drugs and
other routine care and diagnosis, this ended up to
CAN$36,125 for the whole year. Costs were highest
in the ﬁrst month with an average of CAN$5455,
whereas costs for the subcutaneous maintenance
treatment averaged CAN$3043 on the second
month declining to CAN$2304 in the 12th month.
 
Follow-up  costs.
 
Follow-up costs diminish also
over time, with more intensive surveillance during
the ﬁrst year after treatment. Resources used were
partly based on patient charts and for the longer
period upon standard routine practice at the Royal
Victoria Hospital. This yielded an annual average
cost of CAN$277 for the year after interferon treat-
ment (year 2) or after surgery in the control arm
declining to CAN$133 in year 3 to 5 and to
CAN$90 yearly afterward until recurrence.
 
Cost of a recurrence.
 
Standard costs for recurrence
were built from expert opinion of the oncology staff
at the Royal Victoria Hospital. An event tree was
created with the following mix of exclusive thera-
peutic strategies among patients: out of 100 patients
52 would receive chemotherapy, 14 would receive
watchful waiting after surgery for recurrence, 27
would receive palliative care only, and 7 would
receive radiotherapy.
Cost of chemotherapy and radiotherapy were
derived from the Quebec Ministry of Health APR-
DRG System. Palliative care was assumed to be
30 days. This is in line with Hillner et al. [11] who
used a 1-month duration for terminal care and
González-Larriba et al. [14] who used a 3-week
duration.
The cost for palliative care or end-stage disease
care was based on the per diem cost of the palliative
care unit at the Royal Victoria Hospital at
CAN$244 per day. Non-hospital-based ambulatory
care was not included.
By multiplying the proportion of patients receiv-
ing each therapy and assuming that all patients
would receive 30 days of palliative care we obtained
an overall cost of a recurrence, including end-stage
care, of CAN$12,304 over the last 12-month period
with the chemotherapy strategy accounting for
63%, the palliative-care-only strategy for 17%, and
the total cost of the radiotherapy and watchful
waiting strategies accounting both for 10% of the
total cost of a (metastatic) recurrence.
 
Quality of Life
 
Utility estimates for the health states interferon
therapy (induction 
 
+
 
 maintenance) and recurrence
followed by death within 1 year were assessed by
face-to-face interviews in pharmacies by the same
interviewer on a sample of 104 respondents drawn
from the general population in Montreal and two
other urban locations in Quebec, using the TTO
method with the aid of a visual slider prompt. This
reﬂects therefore more urban population prefer-
ences. Large variations were, however, observed
among respondent’s responses resulting in wide
standard deviations of the measures.
 
Results
 
Survival
 
The most striking fact when looking at the graph in
Figure 2 is the long survival period for a number of
patients and the fact that most of the gain in sur-
 
Figure 2
 
Survival from E1684 and model extrapolation. IFN,
interferon.
35-year survival extrapolation
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vival is seen after the trial period
 
.
 
 Therefore hypoth-
eses about the post-trial survival extrapolation play
a crucial role.
 
Quality of  Life
 
Compared to a recent estimate of preferences by
Kilbridge et al. [16] on a sample of patients with
melanoma using a standard gamble method, our
estimates using a TTO approach are lower in abso-
lute values, as would be expected. The ratio of the
mean utility of interferon treatment to recurrence is,
however, higher in our sample.
The mean utility during interferon treatment was
equal to 0.52 (
 
±
 
0.29) and the median equal to 0.58.
For recurrence we obtained a mean utility of 0.23
(
 
±
 
0.23) but a median of 0.08 reﬂecting the fact that
a sizable minority of respondents gave a very low
estimate for that state. RFS was assumed equal to 1
by default and death was anchored at 0.
 
Cost-Effectiveness
 
The results are presented as the mean ICER, which
corresponds to the following formula:
where 
 
C
 
 
 
=
 
 mean cost, 
 
E
 
 
 
=
 
 mean effectiveness,
IFN 
 
=
 
 interferon treatment, NT 
 
=
 
 no adjuvant
treatment.
The results are calculated for a 7-year period cor-
responding to the follow-up period of the E1684
C C
E E
IFN NT
NT NT
-
-
 
trial (Table 2) and for a 35-year period (Table 3),
which corresponds roughly to the expected lifetime
of a 50-year-old person. Effectiveness is measured
either as life-years gained or quality-adjusted life-
years (QALYs) gained using the mean TTO utility
per health state as a weight. Costs, life-years, and
QALYs are discounted at 3% per year and
expressed in CAN$1999.
 
Sensitivity Analysis
 
Deterministic.
 
Obviously the ICER per QALY is
quite sensitive to the utility assigned to the different
health states, to the cost, dose or unit price, of inter-
feron and the discount rate (Table 4). In most cases
the 7-year estimates are close or above CAN$50,000
per QALY whereas the 35-year estimates do not go
beyond CAN$35,000 in the worst case. The varia-
tion is generally higher for the 7-year period than for
the 35-year period except for the discount rate for
which the ICER increases linearly with the discount
rate, without however, reaching high values at
35 years even for a 10% discount rate on the con-
trary to results over the 7-year time horizon.
 
Stochastic  sensitivity  analysis.
 
The results of the
stochastic sensitivity analysis conﬁrm the baseline
estimates and the univariate sensitivity results, with
the long-term ICERs much more favorable than
those obtained from the trial period (Table 5).
The distribution of the ICER per QALY at
7 years and 35 years are shown in the Figure 3 and
Figure 4.
 
Table 2
 
Incremental cost-effectiveness of  high-dose interferon therapy in stage II–III melanoma for 100 patients over 7 years
(CAN$)
 
C E
 
D
 
C
 
D
 
E
 
D
 
C/
 
D
 
E (ICER)
LY discounted
IFN 3775,121 354 LY 2809,609 61 LY 46,059
No IFN 965,512 293 LY — — —
QALY discounted
IFN 3775,121 262 QALY 2809,609 51 QALY 55,090
No IFN 965,512 211 QALY — — —
 
C, cost; E, effectiveness; ICER, incremental cost-effectiveness ratio; IFN, interferon; LY, life-years; QALY, quality-adjusted life-years.
 
Table 3
 
Incremental cost-effectiveness of  high-dose interferon therapy in stage II–III melanoma for 100 patients over 35 years
(CAN$)
 
C E
 
D
 
C
 
D
 
E
 
D
 
C/
 
D
 
E (ICER)
LY discounted
IFN 3982,606 698 LY 2870,649 200 LY 14,353
No IFN 1111,958 498 LY — — —
QALY discounted
IFN 3982,606 640 QALY 2870,649 205 QALY 14,003
No IFN 1111,958 435 QALY — — —
 
C, cost; E, effectiveness; ICER, incremental cost-effectiveness ratio; IFN, interferon; LY, life-years; QALY, quality-adjusted life-years.
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Figure 3
 
Distribution of  the incremental cost-effetiveness ratio per
quality-adjusted life-year at 7 years with ﬁxed discount rate of  3%.
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Figure 4
 
Distribution of  the incremental cost-effetiveness ratio per
quality-adjusted life-year at 35 years with ﬁxed discount rate of  3%.
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Table 4
 
Deterministic sensitivity results
 
Variable Baseline Value
QALY discounted 3%
7 years 35 years
Annual follow-up costs CAN$277–133–90
 
¢
 
3 54,776 14,185
 
=
 
 0 54,694 13,943
Cost of  recurrence CAN$12,304
 
+
 
50% 52,073 13,614
 
=
 
 0 57,338 14,345
Utility
IFN treatment 0.52 0.83
Recurrence 0.23 0.60
Relapse-free 1 0.96
48,766 13,187
IFN treatment 0.58
Recurrence 0.08
Relapse-free 1
51,080 13,127
Discount rate* 0% 48,497 9,213
3% 3% 55,090 14,003
6% 61,425 19,933
10% 79,481 30,620
Post-trial recurrence rates control/IFN (in annual %) 2.5% both
Early carry-over 1.825/2.5 NA 14,982
Late crossover 1.825/5.0 NA 23,058
Early crossover 0/5.0 NA 35,387
Optimistic model 1.825 NA 13,635
Cure model 0 NA 11,900
Drop-dead model 25 NA 27,125
Interferon dose CAN$36,125
100%/8$ MU 29,885 9,203
80% 23,485 7,299
60% 17,086 5,396
100%/16$ MU 61,881 18,722
80% 49,082 14,914
60% 36,283 11,107
 
*Results for intermediate discount rates fell within the above values range.
IFN, interferon; NA, not applicable; QALY, quality-adjusted life-years.
 
Table 5
 
Probabilistic sensitivity analysis results
 
ICER
Discount rate
0% (Mean 
 
± 
 
STD) 3% (Mean 
 
± 
 
STD) 6% (Mean 
 
± 
 
STD)
LY gained (7 years) 41,684 
 
± 
 
9174 45,472 
 
± 
 
9946 49,411 
 
± 
 
11,278
LY gained (35 years)  9391 
 
± 
 
2454 13,700 
 
± 
 
3350 18,794 
 
± 
 
4,405
QALYs (7 years) 41,256 
 
± 
 
10,003
 
+
 
45,719 
 
± 
 
10,915 51,005 
 
± 
 
12,925
QALYs (35 years)  9543 
 
± 
 
2554
 
+
 
13,919 
 
± 
 
3485 19,239 
 
± 
 
4,609
 
ICER, incremental cost-effectiveness ratio; STD, standard deviation; LY, life-years; QALY, quality-adjusted life-years.
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We also ran a regression analysis on the simula-
tion results in order to verify the sensitivity of the
ICER to the various stochastic parameters. It
appears that for life-year gained and QALYs, apart
from the discount rate, the cost of interferon, and
the post-trial relapse/death rate are the most inﬂu-
ential parameters at 35 years (correlations of 0.869
and 0.379, respectively), whereas at 7 years, it is the
cost of interferon and the utility associated with the
interferon treatment that are most inﬂuential (cor-
relations of 0.910 and –0.352, respectively).
 
Discussion
 
Until the advent of interferon in the therapy of stage
III melanoma, few other options besides surgery fol-
lowed by observation existed. Adjuvant therapy
interferon is intended to increase the medium-to-
long-term survival by preventing (systemic) recur-
rence with the lowest toxicity possible. The cost of
HDI is, however, high, accounting for about 71% of
the discounted postsurgery costs over a simulated
lifetime of 35 years. A number of other studies have
assessed the cost–effectiveness of HDI therapy, all of
which were based on the published E1684 trial data
with long-term extrapolation of costs and beneﬁts.
Our cost of recurrence including end-stage palli-
ative treatment are very close to the estimates of
González-Larriba et al. [14] (
 
ª
 
CAN$11,486) but
much less than the US hypothetical costs used by
Hillner et al. [11] (
 
ª
 
$US65,000) as can be seen in
Table 6.
Compared to the Hillner [11] and González-
Larriba et al. [14] studies we found a higher average
number of undiscounted life-years gained in our
baseline estimates, comparable to those found by
Messori et al. [15] who used a parametric Gom-
pertz survival model (3–3.3 years vs. 1.8–1.9 years).
Extrapolation of the survival seen in the E1684 trial
is, however, problematic as the last years of follow-
up (year 6 and beyond) in the trial were based on a
small number of patients at risk and showed nearly
no events, resulting in an apparent “ﬂat” survival
curve from year 6 on in both arms.
Therefore the weight given by the extrapolation
exercise to these end-of-trial results does inﬂuence
the calculation of the incremental beneﬁts. Also the
long-term disease-speciﬁc recurrence rate is subject
to debate, as it is not known whether this could dif-
fer between the two arms.
Utility measurements also differ widely in their
results as they are based on different elicitation
methods—interview, TTO and standard gamble—
and on different populations—clinical experts,
early-stage melanoma patients and general public.
This would not be a cause for concern, were it not
for the large inﬂuence of the utility values of the
treatment and relapse states on the overall results.
Furthermore, one may wonder whether to use
median rather than mean group values, given the
large standard deviations observed in both the
patient and general population samples, which pin-
points to the existence of subgroups of respondents
with widely different preferences.
 
Conclusions
 
Despite these uncertainties all simulation studies
point to an average gain of 2 to 3 life years over a
time span of 35 years. Interestingly the more recent
E1690 trial demonstrated an absolute higher sur-
vival both in the HDI arm as in the observational
arm, which might be because of changes in practice
(better compliance of interferon regimen, use of
interferon rescue therapy, improved clinical man-
agement, etc.). Future work will be needed to focus
on these newer data as well, building on the knowl-
edge gained until now.
More data are also needed on the incidence of
local versus systemic recurrences, as these have not
been distinguished in the different models and trials
published to date. Furthermore, the question of
whether LDI could be used with comparative sur-
vival beneﬁts remains contentious as several trials
have proved inconclusive, including the E1690 trial,
where, although an improvement of RFS was dem-
onstrated [8], it did not reach signiﬁcance after
adjustment for stage and nodal status.
 
Table 6
 
Comparison of  treatment costs between models of  high-dose interferon treatment in melanoma (in CAN$)
 
References
IFN therapy
(year 1)
RFS
(year 1)
RFS
(year 2–5)
RFS
(year 
 
>
 
 5) Recurrence Terminal stage
Crott et al. [18] CAN$36,125 CAN$277 CAN$133 CAN$90 CAN$4984 CAN$7320
González-Larriba et al. [14] CAN$29,916 CAN$921 CAN$460 CAN$295 CAN$4275 CAN$7211
Messori et al. [15] CAN$29,700 0 0 0 0 0
Hillner et al. [11]* CAN$47,028 0 0 0 CAN$108,000 CAN$13,500
 
*Recurrence costs over 1.6 years, authors’ calculations: 1 $US 
 
= 1.35 CAN$, 1 EUR = 1.67 CAN$.
IFN, interferon; RFS, relapse-free survival.
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Quality-of-life of patients in different health
states, especially when undergoing HDI therapy
with its associated frequent toxicity should be part
of the clinical and economic evaluation process.
To date only two sets of utility measures have been
published for interferon therapy in patients with
melanoma, which differ widely in the population
assessed and elicitation methods used, and therefore
give quite different results [16,18], although our
ICER estimates at 35 years proved remarkably sta-
ble when using either set of quality-of-life utilities
but showed much greater variation when estimated
over 7 years. Given the long time horizon of 35 years
for survival, the cost of recurrence and end-stage care
[9] have less impact on overall results than the choice
of discounting and overall cost of interferon therapy.
Also our cost estimates for Quebec are similar to
those observed in Europe but represent only half the
cost of similar events in the United States as pre-
sented by Hillner et al. [11].
The short-term ICER based only on trial data up
to 7 years are relatively high at an average cost of
CAN$46,059 per life-year gained, but of the same
order of magnitude as found by Hillner et al. [11] in
the United States, whereas over the longer term the
ICER improves signiﬁcantly to about CAN$14,353
per life-year gained, quite similar to the ﬁgures
found by Messori et al. [15], but below those of
González-Larriba et al. [14]. This converging evi-
dence of the ICER value per life-year gained points
to a good long-term “value for money” ratio for
HDI in stage III melanoma patients at least for an
initial survival gain as observed in ECOG E1684
trial and provided patients treated with interferon
do not have a higher metastatic relapse rate after the
trial period. These results hold, however, only in the
long term, when taking into account the expected
gain in survival after the trial follow-up period.
Were we to rely only on the trial-based ICER either
expressed as life-years gained or as QALYs gained,
one would have had ground to be more skeptic, if
not to reject altogether the new treatment. This
again proves that long-term effects on survival
beyond the trial horizon should be taken into
account in economic evaluations of new cancer
therapies when a large number of patients have not
reached the primary end point.
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